MOUNTAIN VIEW, Calif., July 17, 2012 /PRNewswire/ -- Xlumena, Inc. announces that it has received CE Mark approval to market its AXIOS Stent and Delivery System for biliary tract drainage. The device ...

The US Food and Drug Administration (FDA) has allowed marketing of the Xlumena, Inc's Axios Stent and Delivery System for treating pseudocysts (fluid and tissue filled cavities) that form in the ...

Boston Scientific Corporation announced today the commercial launch of the AXIOS Stent and Electrocautery Enhanced Delivery System. It is designed to help physicians manage serious complications from ...

MOUNTAIN VIEW, Calif., May 15, 2012 /PRNewswire/ -- Xlumena, Inc. announces the publication of a scientific paper describing the first human study of the AXIOS™ Stent and Delivery System. The article, ...

Axios Stent and Electrocautery Enhanced Delivery System--Courtesy of Boston Scientific Boston Scientific ($BSX) launched the Axios Stent and Electrocautery Enhanced ...

In a bid to extend its footprint in the multibillion-dollar endoscopy equipment market, Boston Scientific Corporation BSX has commercially launched its FDA-cleared Axios stent and electrocautery ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA will allow the marketing of the ...

The first stent specifically designed to treat pancreatic pseudocysts yesterday was cleared for marketing by the US Food and Drug Administration (FDA). The Axios stent and delivery system from Xlumena ...

Boston Scientific launched the AXIOS Stent and Electrocautery Enhanced Delivery System. 1. The system is intended to help physicians manage two complications from pancreatitis using a minimally ...

Xlumena's Axios stent and delivery system--Courtesy of Xlumena The FDA has approved Xlumena's AXIOS stent and delivery system to treat pseudocysts of the pancreas. In its press release announcing the ...